Skip to main content
Clinical Trials/NCT00002423
NCT00002423
Completed
Phase 2

A Phase II, Open-Label Trial for Treatment of HIV Infection in Subjects Who Have Failed Initial Combination Therapy With Regimens Containing Indinavir or Nelfinavir: Combination Therapy With 3TC (150 Mg BID), Abacavir (300 Mg BID) and Amprenavir (1200 Mg BID) Plus Either Nelfinavir (1250 Mg BID) or Indinavir (800 Mg TID) for 48 Weeks

Glaxo Wellcome8 sites in 1 country100 target enrollmentMarch 1999

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
HIV Infections
Sponsor
Glaxo Wellcome
Enrollment
100
Locations
8
Status
Completed
Last Updated
20 years ago

Overview

Brief Summary

This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.

Detailed Description

Patients experiencing virologic failure while receiving an IDV-containing antiretroviral regimen will receive the 3TC/ABC/APV/NFV combination. Patients experiencing virologic failure while receiving an NFV-containing antiretroviral regimen will receive the 3TC/ABC/APV/IDV combination.

Registry
clinicaltrials.gov
Start Date
March 1999
End Date
TBD
Last Updated
20 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Glaxo Wellcome

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (8)

Loading locations...

Similar Trials